Skip to content

iBio Stock Surges After Planet Biotech COVID-19 Agreement

Biotechnology company iBio Inc (IBIO) has announced an exclusive license agreement with Planet Biotechnology for the development of Planet’s COVID-19 therapeutic candidate.

While there was little in the way of detail provided regarding the agreement, the company said that it is a worldwide one and will see Planet paid pre-specified amounts upon the completion of certain milestones.

“We see tremendous opportunity in our partnership with Planet to develop this novel immunoadhesin molecule as a potential COVID-19 disease treatment,” said Tom Isett, Chairman and CEO of iBio.

“We believe the molecule may be effective against SARS-CoV-2 infection, and that it has the potential to be rapidly re-designed in the FastPharming® System to address mutations in the current virus, if any, as well as future coronaviral diseases.”

iBio’s share price…

The news has sent iBio’s stock surging almost 20% higher premarket on Friday. It is currently trading at $2.52 per share after Thursday’s close at $2.11.

The company has seen enormous growth this year with its stock up over 700% for the year to date.

Planet Biotechnology President and CEO, Elliot Fineman said on the agreement that “iBio is an ideal partner for Planet, offering experience in manufacturing plant-based biopharmaceuticals and rapid scale-up capabilities. We are eager to support iBio in the pre-clinical development of ACE2-Fc.”

Sam Boughedda
Sam Boughedda
Team Member

Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples. 

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.